Physician profile
Mitchell B Bernsen
NPI 1275523631
$17,101.43
in general payments reported to CMS, 2019-2025
42 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $386 · 2021: $3,651 · 2022: $3,081 · 2023: $2,628 · 2024: $2,878 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,194 · Education: $299 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,194.34 |
| Education | $298.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,963.21 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,942.95 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,889.95 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gastrogpo, LLC | $1,745.98 | 2022 | |
| Pfizer INC. | $767.01 | 2019-2025 | |
| Gilead Sciences, INC. | $498.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.31 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Genzyme Corporation | $346.15 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.57 | 2022-2025 | Dupixent |
| Celgene Corporation | $258.44 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $241.57 | 2025 | Rezdiffra |
| Allergan, INC. | $235.44 | 2019-2020 | |
| Ardelyx, INC. | $215.98 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $203.56 | 2019-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $199.39 | 2024-2025 | Vegzelma, Zymfentra |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,586.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Bernsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.